Bayesian approach to noninferiority trials for proportions

Journal of Biopharmaceutical Statistics

Volumn 21, Issue 5, 2011, Pages 902-919

  Gamalo, Mark A ^a   Wu, Rui ^b   Tiwari, Ram C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Bayesian criterion; Bayesian paradigm; Beta binomial; Noninferiority margin; Normal approximation

Indexed keywords

ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; BAYESIAN LEARNING; LEARNING; PRIORITY JOURNAL; PROBABILITY;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; HUMANS; MODELS, STATISTICAL; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 80051761935     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2011.589646     Document Type: Article

References (15)

1. CDER/FDA Guidance for Industry. (2010). Noninferiority clinical trials. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM20 2140.pdf
2. CDRH/FDA Guidance for Industry and FDA Staff. (2010). Guidance for the use of Bayesian statistics in medical device clinical trials. Available at http://www.fda.gov/ MedicalDevises/DeviceRegulationandGuidance/ GuidanceDocuments/ucm071072.htm (last accessed July 2011)
3. DAgostino, R. B., Massaro, J. M., Sullivan, L. M. (2003). Noninferiority trials: Design concepts and issues the encounters of academic consultants in statistics. Statistics in Medicine 22:169-186. (Pubitemid 36163579)
4. Hasselblad, V., Kong, D. (2001). Statistical methods for comparison to placebo in activecontrol trials. Drug Information Journal 35:435-449. (Pubitemid 32524896)
5. Hobbs, B. P., Carlin, B. P., Mandrekar, S., Sargent, D. J. (2011). Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics, in press.
6. Holmgren, E. B. (1999). Establishing equivalence by showing that a prespecified percentage of the effect of the active control over placebo is maintained. Journal of Biopharmaceutical Statistics 9:651-659. (Pubitemid 29535953)
7. Hung, H. M. J., Wang, S. J., Tsong, Y., Lawrence, J., ONeill, R. T. (2003). Some fundamental issues with noninferiority testing in active controlled clinical trials. Statistical in Medicine 22:213-225. (Pubitemid 36163582)
8. Hung, H. M. J., Wang, S. J., ONeill, R. T. (2005). Regulatory perspective on choice of margin and statistical inference issue in noninferiority trials. Biometrical Journal 47:28-36. (Pubitemid 40390436)
9. Rohmel, J. (1998). Therapeutic equivalence investigations: Statistical considerations. Statistics in Medicine 17:1703-1714. (Pubitemid 28409926)
10. Rothman, K. J., Michels, K. B. (1994). The continued unethical use of placebo controls. New England Journal of Medicine 331:394-398. (Pubitemid 24233862)
11. Simon, R. (1999). Bayesian design and analysis of active control clinical trials. Biometrics 55:18-21.
12. Temple, R., Ellenberg, S. S. (2000). Placebo controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 133:455-463.
13. Wang, S.-J., Hung, H. M. J., Tsong, Y.-T. (2002) Utility and pitfalls of some statistical methods in active controlled clinical trials. Controlled Clinical Trials 23:15-28. (Pubitemid 34164355)
14. World Medical Association. (2000). Declaration of Helsinki. Ethical principles for medical research involving human subjects. Journal of the American Medical Association 284:3043-3045.
15. Zhang, H., Rojas, H. A. G., Cuervo, E. C. (2010). Confidence and credibility intervals for the difference of two proportions. Revista Colombiana de Estadstica 33:63-88.